Immuno therapy for COVID-19 induced lung fibrosis(Ceapro/McMaster University)

N/A

Report date: 2025/01/26 19:01:30

Base Information

Drug NameImmuno therapy for COVID-19 induced lung fibrosis(Ceapro/McMaster University)
Drug Alias Namepolyglycystic Glucose-YBG (PGX-YBG)PGX-YBG
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Pulmonary FibrosisLung Diseases, Interstitial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCeapro Inc
China Registration ClassN/A

Develop Information

Active CompaniesCeapro IncMcmaster University
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Pulmonary FibrosisLung Diseases, Interstitial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A